The U.S. District Court for the District of Delaware has determined that Forest Laboratories‘ patent covering escitalopram, the active ingredient in Lexapro, is both valid, enforceable and infringed by Ivax/Teva’s proposed generic product. The ruling confirms patent rights for Lexapro, which expire in March 2012, for Forest and its partner H. Lundbeck A/S of Denmark....